Breaking News, Collaborations & Alliances

Pfizer Acquires NextWave

Picks up portfolio, new ADHD treatment

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Pfizer will acquire NextWave Pharmaceuticals, a privately held, specialty pharma company focused on ADHD and CNS drugs. NextWave is the developer of Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. The company holds exclusive North American commercialization rights to Quillivant XR, which received FDA approval in September 2012, and is expected to be available in U.S. ph...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters